Genetic advances in medicine: Has the promise been fulfilled in general practice?

British Journal of General Practice

Volumn 62, Issue 596, 2012, Pages 120-121

  Walter, Fiona M ^a   Emery, Jon D ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C9; DNA; NICOTINE; WARFARIN;

BEHAVIOR CHANGE; BIOMEDICINE; BLEEDING; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; EDITORIAL; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE INTERACTION; GENE MUTATION; GENERAL PRACTICE; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEMOGLOBINOPATHY; HEREDITY; HETEROZYGOTE; HUMAN; HUMAN GENOME PROJECT; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRENATAL CARE; PROPHYLAXIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

GENERAL PRACTICE; GENETIC TESTING; GENETICS, MEDICAL; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; PEDIGREE; PHARMACOGENETICS; RISK ASSESSMENT;

EID: 84857718098     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp12X629955     Document Type: Editorial

References (15)

1. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. New Engl J Med 2010; 362(21): 2001-2011.
2. Human Genomics Strategy Group. Building on our inheritance: genomic technology in healthcare. London: Department of Health, 2012
3. Emery J, Watson E, Rose P, Andermann A. A systematic review of the literature exploring the role of primary care in genetic services.Fam Pract 1999; 16(4): 426-445. (Pubitemid 29410766)
4. Brown K, Dormandy E, Reid E, et al. Impact on informed choice of offering antenatal sickle cell and thalassaemia screening in primary care: a randomized trial. JMed Screen 2011; 18(2): 65-75.
5. Qureshi N, Humphries SE, Seed M, et al. Identification and management of familial hypercholesterolaemia: what does itmean to primary care?Br J Gen Pract 2009; 59(567): 773-776.
6. Johnson EG, Horne BD, Carlquist JF, Anderson JL. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Mol Diagn Ther 2011; 15(5): 255-264.
7. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 2010; 11(6): 507-509.
8. National Human Genome Research Institute. http://www.genome.gov/ gwastudies/ (accessed 13 Feb 2012).
9. Khoury MJ, Gwinn M, Bowen MS, Dotson WD. Beyond base pairs to bedside: a population perspective on how genomics can improve health. Am J Public Health 2011. [Epub ahead of print].
10. Rafi I, Qureshi N, Lucassen A, et al. 'Over-the-counter'genetic testing: what does it really mean for primary care? Br J Gen Pract 2009; 59(561): 283-287.
11. Emery JD, Walter FM, Ravine D. Family history: the neglected risk factor in disease prevention. Med J Aust 2010; 192(12): 677-678.
12. Reid GT, Walter FM, Brisbane JM, Emery JD. Family history questionnaires designed for clinical use: a systematic review. Public Health Genomics 2009; 12(2): 73-83.
13. Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151(12): 878-885.
14. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to- consumer genomewide profiling to assess disease risk. New Engl J Med 2011; 364(6): 524-534.
15. Claassen L, Henneman L, Janssens AC, et al. Using family history information to promote healthy lifestyles and prevent diseases; a discussion of the evidence. BMC Public Health 2010; 10: 248.